Related Experiment Video
Updated: May 27, 2026
In vitro Organoid Culture of Primary Mouse Colon Tumors
Published on: May 17, 2013
JAK/STAT/SOCS-signaling pathway and colon and rectal cancer
Martha L Slattery1, Abbie Lundgreen, Susan A Kadlubar
1Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah 84108, USA. marty.slattery@hsc.utah.edu
Abstract:
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway is involved in immune function and cell growth. We evaluated the association between genetic variation in JAK1 (10 SNPs), JAK2 (9 SNPs), TYK2 (5 SNPs), suppressors of cytokine signaling (SOCS)1 (2 SNPs), SOCS2 (2 SNPs), STAT1 (16 SNPs), STAT2 (2 SNPs), STAT3 (6 SNPs), STAT4 (21 SNPs), STAT5A (2 SNPs), STAT5B (3 SNPs), STAT6 (4 SNPs) with risk of colorectal cancer. We used data from population-based case-control studies (colon cancer n = 1555 cases, 1,956 controls; rectal cancer n = 754 cases, 959 controls). JAK2, SOCS2, STAT1, STAT3, STAT5A, STAT5B, and STAT6 were associated with colon cancer; STAT3, STAT4, STAT6, and TYK2 were associated with rectal cancer. Given the biological role of the JAK/STAT-signaling pathway and cytokines, we evaluated interaction with IFNG, TNF, and IL6; numerous statistically significant associations after adjustment for multiple comparisons were observed. The following statistically significant interactions were observed: TYK2 with aspirin/NSAID use; STAT1, STAT4, and TYK2 with estrogen status; and JAK2, STAT2, STAT4, STAT5A, STAT5B, and STAT6 with smoking status and colon cancer risk; JAK2, STAT6, and TYK2 with aspirin/NSAID use; JAK1 with estrogen status; STAT2 with cigarette smoking and rectal cancer. JAK2, SOCS1, STAT3, STAT5, and TYK2 were associated with colon cancer survival (hazard rate ratio (HRR) of 3.3 95% CI 2.01,5.42 for high mutational load). JAK2, SOCS1, STAT1, STAT4, and TYK2 were associated with rectal cancer survival (HRR 2.80 95% CI 1.63,4.80). These data support the importance of the JAK/STAT-signaling pathway in colorectal cancer and suggest targets for intervention.
Insights
Genetic variations in the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway genes are linked to colorectal cancer risk and survival. Interactions with lifestyle factors like smoking and NSAID use were also identified, suggesting potential therapeutic targets.
Area of Science:
- Genetics and Molecular Biology
- Oncology
- Immunology
Background:
- The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway regulates immune responses and cell proliferation.
- Dysregulation of this pathway is implicated in various cancers, including colorectal cancer (CRC).
Purpose of the Study:
- To investigate the association between genetic variations in JAK/STAT pathway genes and the risk of developing colon and rectal cancer.
- To explore interactions between these genetic variations and environmental/lifestyle factors.
- To assess the impact of these genetic variations on CRC survival rates.
Main Methods:
- Case-control study design utilizing genetic data from 1555 colon cancer cases and 1956 controls, and 754 rectal cancer cases and 959 controls.
- Analysis of single nucleotide polymorphisms (SNPs) in JAK1, JAK2, TYK2, SOCS1, SOCS2, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6.
- Evaluation of gene-environment interactions with IFNG, TNF, IL6, aspirin/NSAID use, estrogen status, and smoking status.
Main Results:
- Specific JAK and STAT gene variations were significantly associated with colon cancer risk (e.g., JAK2, STAT1, STAT3, STAT6) and rectal cancer risk (e.g., STAT3, STAT4, STAT6, TYK2).
- Significant interactions were found between TYK2 and NSAID use, STAT1/STAT4/TYK2 and estrogen status, and several JAK/STAT genes with smoking status.
- Genetic variations in JAK2, SOCS1, STAT3, STAT5, and TYK2 were associated with improved colon cancer survival, while JAK2, SOCS1, STAT1, STAT4, and TYK2 were linked to rectal cancer survival.
Conclusions:
- The JAK/STAT signaling pathway plays a crucial role in colorectal cancer development and progression.
- Genetic variations within this pathway, along with interactions with lifestyle factors, influence cancer risk and patient outcomes.
- These findings highlight the JAK/STAT pathway as a potential target for novel therapeutic strategies in CRC management.
Related Concept Videos
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:33Hedgehog Signaling Pathway
02:33Hedgehog Signaling Pathway
03:14Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
03:14Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...